5 February 2021 in medRxiv
Summary: Convalescent plasma may benefit immunocompromised individuals with COVID-19, including those with hematologic malignancy. We evaluated the association of convalescent plasma treatment with 30-day mortality in hospitalized adults with hematologic malignancy and COVID-19 from a multi-institutional cohort. 143 treated patients were compared to 823 untreated controls. After adjustment for potential confounding factors, convalescent plasma treatment was associated with improved 30-day mortality (hazard ratio, 0.60; 95% CI, 0.37-0.97). This association remained significant after propensity-score matching (hazard ratio, 0.52; 95% CI, 0.29-0.92). These findings suggest a potential survival benefit in the administration of convalescent plasma to patients with hematologic malignancy and COVID-19.
30 July 2024 in Science Signaling
Obstructive sleep apnea (OSA) is a prevalent sleep disorder that is associated with increased incidence of chronic musculoskeletal pain. We investigated the mechanism of this association in a mouse model of chronic intermittent hypoxia (CIH) that mimics the repetitive hypoxemias of OSA. After 14 days of CIH, both male and female mice exhibited behaviors indicative of persistent pain, with biochemical markers in the spinal cord dorsal horn and sensory neurons of the dorsal root ganglia consistent with hyperalgesic priming. CIH, but not sleep fragmentation alone, induced an increase in macrophage recruitment to peripheral sensory tissues (sciatic nerve and dorsal root ganglia), an increase in inflammatory cytokines in the circulation, and nociceptor sensitization. Peripheral macrophage ablation blocked CIH-induced hyperalgesic priming. The findings suggest that correcting the hypoxia or targeting macrophage signaling might suppress persistent pain in patients with OSA.
25 August 2015 in BMC Medical Education
Few published studies have evaluated the effectiveness of changing the traditional curriculum of several hourly educational sessions per week to an academic half-day (AHD) educational format. This study describes our experience with implementing an AHD format in the Hematology-Oncology Fellowship Program at The University of Texas MD Anderson Cancer Center and evaluates the perceptions that learners had for this format. Using a mixed quantitative and qualitative approach, we evaluated our AHD program using four yearly fellows’ surveys to assess the Hematology-Oncology Fellows’ perceptions of the effectiveness of the AHD format. We analyzed the fellows’ perceptions using descriptive statistics and thematic analysis of the qualitative data collected from the surveys. We used a quality improvement approach by implementing and testing changes to the AHD over 4 years on the basis of the data collected from the yearly fellows’ surveys. We also collected third-year fellows’ Oncology In Training Exam (ITE) scores from 2008 to 2014. We found that the fellows perceived the AHD format favorably; fellows agreed that they had more motivation to attend AHD, more concentration during the sessions, more effective weekly work organization, and increased knowledge retention. We established the reliability of our survey tool (Cronbach’s alpha = 0.83) as well as content and construct validity. We saw an increasing trend in ITE scores since the AHD was implemented. Our results contribute to further understanding the effect of the AHD format on trainees. Using a continuous evaluation and an educational quality improvement strategy, we found that the AHD curriculum was associated with a rising trend in learners’ exam scores and increased learner satisfaction.
4 October 2017 in Open Forum Infectious Diseases
Current IDSA guidelines mandate removal and re-insertion of Central Venous Catheters (CVCs) in the setting of central line associated bloodstream infections (CLABSI) caused by virulent pathogens. However, CVC may be retained in the setting of non-CLABSI. There has been little if any quantitative assessment of the symptom burden associated with CVC removal and insertion. Between 2013 and 2014, we evaluated the rate of CVC removal in 283 cancer patients who presented at our institution with a bloodstream infection (BSI) in the presence of a CVC whereby the positive blood cultures were drawn from the CVC and peripheral vein. In 2015, we collected symptom burden related to CVC removal and insertion procedures in 60 consecutive cancer patients using the MD Anderson Symptom Inventory. The rate of CVC removal in patients with BSI and other non-CVC source was 57% which was identical to that in patients with CLABSI. (P = 0.94). In the 60 patients evaluated for symptom burden, symptoms (such as pain, pressure, distress) were present in up to 57% to 67% of patients undergoing CVC insertion and removal respectively. In 32% of patients, moderate to severe symptoms were reported with a symptom burden level of 4/10 or more. CVC removal occurred unnecessarily in 57% of non-CLABSI patients which was equivalent to that in patients with CLABSI. Catheter removal and insertion produced moderate to severe symptom burden in cancer patients. Physician education need to be reinforced and safe interventions to salvage the vascular access should be explored. J. Rosenblatt, Infective Technologies, LLC: Co-Inventor of the Nitroglycerin-Citrate-Ethanol catheter lock solution technology which is owned by the University of Texas MD Anderson Cancer Center (UTMDACC) and has been licensed by Novel Anti-Infective Technologies, LLC in which Dr. Rosenblatt is a and Shareholder, Licensing agreement or royalty; UT MD Anderson Cancer Center: Co-Inventor of the Nitroglycerin-Citrate-Ethanol catheter lock solution technology which is owned by the University of Texas MD Anderson Cancer Center (UTMDACC) and has been licensed by Novel Anti-Infective Technologies, LLC in which Dr. Rosenblatt is a s and Scientific Advisor, Licensing agreement or royalty; I. Raad, Merck: Grant Investigator, Research grant; Allergan: Grant Investigator, Research grant; Infective Technologies, LLC: Co-Inventor of the Nitroglycerin-Citrate-Ethanol catheter lock solution technology which is owned by the University of Texas MD Anderson Cancer Center (UTMDACC) and has been licensed by Novel Anti-Infective Technologies, LLC in which Dr. Raad is a s and Shareholder, Licensing agreement or royalty.